Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Brooks

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pediatrics|September 24, 2008
Part-time training in pediatric residency programs: principles and practicesMary Beth Gordon, Gail A McGuinness, Bonita F Stanton, et al.
Craniomaxillofacial Trauma & Reconstruction|March 2, 2012
Long-Term Follow-up of a Tessier Number 5 Facial CleftAhmed M Afifi, Risal Djohan, Walter Sweeney, et al.
British Journal of Cancer|October 21, 2016
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, Prunella Blinman, Linda Mileshkin, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
High-Resolution Spatial Transcriptomic Atlas of Mouse Soleus Muscle: Unveiling Single Cell and Subcellular Heterogeneity in Health and DenervationJer-En Hsu, Lloyd Ruiz, Yongha Hwang, et al.
American Journal of Human Genetics|August 23, 2016
Variants in HNRNPH2 on the X Chromosome Are Associated with a Neurodevelopmental Disorder in FemalesJennifer M Bain, Megan T Cho, Aida Telegrafi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pediatrics|September 24, 2008
Part-time training in pediatric residency programs: principles and practicesMary Beth Gordon, Gail A McGuinness, Bonita F Stanton, et al.
Craniomaxillofacial Trauma & Reconstruction|March 2, 2012
Long-Term Follow-up of a Tessier Number 5 Facial CleftAhmed M Afifi, Risal Djohan, Walter Sweeney, et al.
British Journal of Cancer|October 21, 2016
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, Prunella Blinman, Linda Mileshkin, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
High-Resolution Spatial Transcriptomic Atlas of Mouse Soleus Muscle: Unveiling Single Cell and Subcellular Heterogeneity in Health and DenervationJer-En Hsu, Lloyd Ruiz, Yongha Hwang, et al.
American Journal of Human Genetics|August 23, 2016
Variants in HNRNPH2 on the X Chromosome Are Associated with a Neurodevelopmental Disorder in FemalesJennifer M Bain, Megan T Cho, Aida Telegrafi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 3